 |
|
|
|
|
Product Details:
Payment & Shipping Terms:
|
| Name: | Olaparib | Cas: | 763113-22-0 |
|---|---|---|---|
| Mf: | C24H23FN4O3 | Purity: | 99% |
| Appearance: | White Powder | Package: | 1kg/bag Or 25kgs/drum |
| High Light: | Olaparib Active Pharmaceutical Ingredient,763113-22-0 Active Pharmaceutical Ingredient,Olaparib Pharmaceutical Chemicals |
||
Anti-Cancer Pharmaceutical Grade API 99% Olaparib CAS 763113-22-0
Chinese Name: 1-(Cyclopropionyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl) methyl]-2-fluorobenzoyl] piperazine
Chinese alias: Ola Pani; AZD2281
English Name: Olaparib
English alias: 4-[3-(4-Cyclopropane carbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl]-2H-phthalazin-1-one; AZD2281
CAS: 763113-22-0; 937799-91-0
Molecular formula: C24H23FN4O3
Molecular weight: 434.4628
Character: white powder
Content: 99%min
Description Function
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer both as monotherapy or following platinum-based chemotherapy.
Olaparib as a maintenance therapy or monotherapy for the treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. On January 12, 2018, FDA expanded the approved use of Olaparib to include chemotherapy-experienced patients with germline breast cancer susceptibility gene (BRCA) mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer.
| Adenosine | AR | 58-61-7 | ≥99% |
| Uridine | UR | 58-96-8 | ≥99% |
| Cytidine | CR | 65-46-3 | ≥99% |
| Xanthosine 5-monophosphate disodium salt | XMP- Na2 | 25899-70-1 | ≥98% |
| Inosine-5'-monophosphate disodium salt octahydrate | IMP- Na2 | 20813-76-7 | ≥98% |
| Adenosine 5′-monophosphate disodium salt | AMP- Na2 | 4578-31-8 | ≥98% |
| Adenosine 5'-Monophosphatesodiumsalt | AMP- Na | .13474-03-8 | ≥98% |
| 5-Adenylic acid | AMP | 61-19-8 | ≥98% |
| Adenosine 3',5'-cyclic monophosphate | Cyclic AMP,CAMP | 60-92-4 | ≥97% |
| Uridine 5-monophosphate, disodium salt | UMP- Na2 | 3387-36-8 | ≥98% |
| Uridine 5'-monophosphate | UMP | 58-97-9 | ≥98% |
| Cytidine 5''-monophosphate disodium salt | CMP- Na2 | .6757-06-8 | ≥98% |
| Cytidine 5′-monophosphate | CMP | 63-37-6 | ≥98% |
| Citicoline sodium | CDPC-Na | 33818-15-4 | ≥98% |
| uridine 5'-diphosphate disodium salt | UDP-Na2 | 27821-45-0 | ≥95% |
| IDP-K2 | ≥90% | ||
| Inosine-5'-diphosphoric acid disodium salt | IDP-Na2 | 54735-61-4 | ≥90% |
| Cytidine 5'-Diphosphate Trisodium Salt Hydrate | CDP-Na3 | 34393-59-4 | ≥90% |
| Cytidine-5'-diphosphate disodium salt | CDP-Na2 | 54394-90-0 | ≥90% |
| Adenosine 5'-diphosphate dipotassiuM salt | ADP-K2 | 114702-55-5 | ≥95% |
| Adenosine-5'-diphosphate, MonopotassiuM salt | ADP-K | 72696-48-1 | ≥95% |
| Adenosine-5-diphosphate disodium salt | ADP-Na2 | 16178-48-6 | ≥95% |
| Adenosine 5''-diphosphate sodium salt | ADP-Na | 20398-34-9 | ≥95% |
| Adenosine 5''-diphosphate | ADP | 58-64-0 | ≥95% |
| Uridine 5'-triphosphate disodium salt | UTP-Na3 | 19817-92-6 | ≥90% |
| Uridine-5'-triphosphoric acid trisodium salt | UTP-Na2 | 285978-18-9 | ≥90% |
| CTP-Na3 | ≥95% | ||
| Cytidine 5′-triphosphate disodium salt | CTP-Na2 | 36051-68-0 | ≥95% |
| Adenosine 5'-triphosphate disodium salt | ATP-Na2 | 987-65-5 | ≥95% |
| Adenosin-5'-triphosphat | ATP | 56-65-5 |
Contact Person: July
Tel: 25838890
